IL157414A0 - Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture - Google Patents

Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture

Info

Publication number
IL157414A0
IL157414A0 IL15741402A IL15741402A IL157414A0 IL 157414 A0 IL157414 A0 IL 157414A0 IL 15741402 A IL15741402 A IL 15741402A IL 15741402 A IL15741402 A IL 15741402A IL 157414 A0 IL157414 A0 IL 157414A0
Authority
IL
Israel
Prior art keywords
protein
interest
supernatant
secretion
bacterial culture
Prior art date
Application number
IL15741402A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL157414A0 publication Critical patent/IL157414A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15741402A 2001-02-20 2002-02-08 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture IL157414A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10108212A DE10108212A1 (de) 2001-02-20 2001-02-20 Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
PCT/EP2002/001307 WO2002068660A1 (en) 2001-02-20 2002-02-08 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture

Publications (1)

Publication Number Publication Date
IL157414A0 true IL157414A0 (en) 2004-03-28

Family

ID=7674913

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15741402A IL157414A0 (en) 2001-02-20 2002-02-08 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture

Country Status (19)

Country Link
EP (1) EP1364029B1 (de)
JP (1) JP4243104B2 (de)
KR (1) KR100858009B1 (de)
CN (1) CN100500853C (de)
AT (1) ATE314480T1 (de)
AU (1) AU2002231784B2 (de)
BR (1) BRPI0207394B8 (de)
CA (1) CA2438886C (de)
DE (2) DE10108212A1 (de)
DK (1) DK1364029T3 (de)
ES (1) ES2254658T3 (de)
HK (1) HK1065335A1 (de)
IL (1) IL157414A0 (de)
MX (1) MXPA03007114A (de)
NO (1) NO331271B1 (de)
NZ (1) NZ527643A (de)
PE (1) PE20020876A1 (de)
WO (1) WO2002068660A1 (de)
ZA (1) ZA200305869B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP2327718B1 (de) 2003-11-21 2016-03-23 Pfenex, Inc. Verbessertes Expressionssystem mit SEC-System-Sekretion
KR20120076377A (ko) 2004-01-16 2012-07-09 다우 글로벌 테크놀로지스 엘엘씨 슈도모나스 플루오레센스에서의 포유류 단백질의 발현
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
KR101491867B1 (ko) 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2344524B1 (de) 2008-10-02 2019-12-04 Unitargeting Research As Kit zur optimierung der proteinsynthese/sezernierung
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 2型糖尿病の治療用の医薬の製造のためのave0010の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 2型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
KR20160029731A (ko) 2013-03-12 2016-03-15 더 제너럴 하스피탈 코포레이션 변형된 뮐러관 억제 물질(mis) 단백질 및 질환 치료를 위한 그 용도
EP3079712B1 (de) 2013-12-11 2022-02-02 The General Hospital Corporation Verwendung von anti-müller-hormon (amh)-proteine zur kontrazeption und ovariellen reservekonservierung
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341414C (fr) * 1984-03-27 2002-12-31 Paul Tolstoshev Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
CA2255396A1 (en) * 1990-11-08 1992-05-09 Nippon Mining Company Limited Hirudin analog, method of manufacturing thereof and anti-coagulant composition, and secretion vector, transformed microorganisms containing said vector and manufacturing method ofproducts which is produced from said microorganism
WO1995009125A1 (en) * 1992-09-28 1995-04-06 Pehr Harold T Kicker latch for container closures
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP

Also Published As

Publication number Publication date
NZ527643A (en) 2005-07-29
MXPA03007114A (es) 2003-11-18
CN1529757A (zh) 2004-09-15
JP2004518444A (ja) 2004-06-24
ATE314480T1 (de) 2006-01-15
NO331271B1 (no) 2011-11-14
DE10108212A1 (de) 2002-08-22
ES2254658T3 (es) 2006-06-16
PE20020876A1 (es) 2002-11-05
DE60208343T2 (de) 2006-06-22
AU2002231784B2 (en) 2006-10-26
KR20030074842A (ko) 2003-09-19
JP4243104B2 (ja) 2009-03-25
EP1364029B1 (de) 2005-12-28
DK1364029T3 (da) 2006-05-08
NO20033673D0 (no) 2003-08-19
KR100858009B1 (ko) 2008-09-11
CA2438886A1 (en) 2002-09-06
DE60208343D1 (de) 2006-02-02
BRPI0207394B8 (pt) 2021-05-25
CA2438886C (en) 2013-07-23
WO2002068660A1 (en) 2002-09-06
BR0207394A (pt) 2004-02-10
CN100500853C (zh) 2009-06-17
ZA200305869B (en) 2004-06-25
NO20033673L (no) 2003-10-17
HK1065335A1 (en) 2005-02-18
BRPI0207394B1 (pt) 2015-06-16
EP1364029A1 (de) 2003-11-26

Similar Documents

Publication Publication Date Title
HK1065335A1 (en) Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
EP1470236A4 (de) Verfahren und zusammensetzungen für die proteinexpression und reinigung
WO2003003984A8 (en) Novel proteins and nucleic acids encoding same
WO2005003313A8 (en) Methods and compositions for enhanced protein expression and purification
AU2003239365A1 (en) Recombinant glycosyltransferase fusion proteins
AU2002367147A1 (en) Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
AU2002349231A1 (en) Methylotrophic bacterium for the production of recombinant proteins and other products
AU2002232803A1 (en) Expression system for recombinant proteins
AU2003254680A1 (en) Staphylococcal nuclease fusion proteins for the production of recombinant peptides
WO2006097708A3 (en) Affinity purification of protein
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU3768199A (en) Human protease associated proteins
GB0116460D0 (en) Biological products
EP1572995A3 (de) Neue proteine und nukleinsäuren zur kodierung dieser
EP1451367A4 (de) Engineering von leader-peptiden für die sekretion von rekombinanten proteinen in bakterien
AU2002230298A1 (en) Systems for expression of heterologous proteins in m. capsulatus
AU2002356339A1 (en) Soluble recombinant protein production
AU2003226907A1 (en) Method for the preparation of recombinant mammalian heparin-binding protein (hbp)
AU2001251132A1 (en) Expression of uncoupling protein (ucp) in plants
WO2003016465A3 (en) Cell cycle regulator protein
AU2003255988A1 (en) Yeast protein expression secretion system
AU2002328222A1 (en) Purified bacterial polypeptides involved in protein processing
IL204767A (en) Stable chimeric oligomeric proteins for denture and protease resistant
AU2002330857A1 (en) Novel proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed